Navigation Links
Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes
Date:8/6/2009

diately prior to the date of the redemption notice.

Goldman, Sachs & Co. is acting as the sole book-running manager for these offerings. Barclays Capital Inc., J.P. Morgan Securities Inc., and Lazard Capital Markets LLC are acting as co-managers. The common stock offering and the convertible senior note offering are being conducted as separate public offerings by means of separate prospectus supplements, and neither of these offerings is contingent upon the consummation of the other. Onyx expects to close the transactions on or about August 12, 2009, and each closing is subject to the satisfaction of customary closing conditions.

These offerings are being made pursuant to an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission (the "SEC"). For each offering, a prospectus supplement and accompanying prospectus describing the terms of such offering have been filed with the SEC. Before investing in either offering, interested parties may read the prospectus supplement and the accompanying prospectus for such offering and the other documents Onyx has filed with the SEC. These documents are incorporated by reference in the prospectus supplement and the accompanying prospectus and provide more complete information about Onyx and the offering. Copies of the prospectus supplements may be obtained from Goldman, Sachs & Co., Prospectus Department, 85 Broad Street, New York, NY 10004, telephone: 1-866-471-2526, facsimile 1-212-902-9316 or by emailing prospectus-ny@ny.email.gs.com. Electronic copies of the prospectus supplements may be obtained by visiting EDGAR on the SEC website at www.sec.gov.

This communication shall not const
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... is rarely simple. From crop yields to disease risks, ... those considered "complex traits." Just as for heightthe textbook ... particular human disease are shaped by multiple genetic and ... involved. To track down such genes, geneticists typically mate ... large mouse and a small mouseand then study their ...
(Date:9/19/2014)... than electricity, to move data would consume much ... growing concern as chips, transistor counts rise. , ... light emitters, modulators, and detectors emitters ... source for optical chips is molybdenum disulfide (MoS2), ... a single, atom-thick layer. Other experimental on-chip light ...
(Date:9/19/2014)... NEW YORK , Sept. 19, 2014  An ... common forms of inherited neuropathies – Charcot-Marie-Tooth disease (CMT) ... feet and legs, causing extreme muscle atrophy, weakness, and ... in the US and millions worldwide. CMT is a ... use of their legs, requiring mobility devices such as ...
(Date:9/19/2014)... SAN FRANCISCO , Sept. 19, 2014 /PRNewswire/ ... announced results from preclinical studies characterizing the analgesic ... oral, peripherally-acting kappa opioid receptor agonist molecules. The ... molecule polymer medicinal chemistry platform. The ... described in the medical literature. 1,2 Kappa ...
Breaking Biology Technology:Want to link genes to complex traits? Start with more diversity 2Toward optical chips 2Toward optical chips 3September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5
... , , , , Efficiency of the standard protocols (1,2) ... (3) , , Propagate M13 ... For producing M13 ssDNA, mix 2.5 ml plating bacteria ... at 4 C for no more than 3 days) , ...
... , , , , Introduction ... , , , , , ... is an important part of your application. Many variables must be considered, , ... evaporation, and accessory chiller—so it's no surprise to find more , ...
... , To ensure that maximum transfection rates are achieved, the electroporation , ... , below for determining the ideal electroporation parameters as simply and , ... , Brochure available upon request., , , ... Field strength , ...
Cached Biology Technology:M13/Phagemid DNA Extraction Protocol 2Optimizing Büchi® Rotary Evaporator Applications 2Optimizing Büchi® Rotary Evaporator Applications 3Optimizing Büchi® Rotary Evaporator Applications 4Optimizing Büchi® Rotary Evaporator Applications 5Optimizing Büchi® Rotary Evaporator Applications 6Optimizing Büchi® Rotary Evaporator Applications 7Optimizing Büchi® Rotary Evaporator Applications 8
(Date:9/21/2014)... Contrary to what was previously thought, newborn immune T ... response to bacteria, according to a new study led ... very differently to that of adults, babies may still ... the study published in the journal Nature Medicine ... several different types of immune cells, including neutrophils which ...
(Date:9/19/2014)... researchers from several Harvard University labs in collaboration ... aspiring researchers with the intellectual raw materials needed ... soft, flexible materials. , With the advent of ... in manufacturing technology, soft robotics is emerging as ... conventional rigid robot design, but working with pliable ...
(Date:9/19/2014)... of years has adapted to the arctic cold, and then ... dangerous for you. , This is happening to the small ... substance, called nonylphenol, comes from the use of certain detergents, ... endocrine disruptor, but when entering the worm it has another ... cells in its body from cold damage. , Enchytraeus ...
Breaking Biology News(10 mins):Immune system of newborn babies is stronger than previously thought 2Soft robotics 'toolkit' features everything a robot-maker needs 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... researchers at Kansas State,University, with collaboration from Epitopix ... against E. coli O157 in beef ... focus on the post-harvest food safety,aspect, whether it,s ... Thomson of,K-State,s College of Veterinary Medicine. Thomson is ...
... health research by providing a goldmine of stored human biological ... we make better use of these invaluable resources by collaborating ... theme of an international conference being held in March 2009. ... use of biobanks through harmonization? The conference ...
... at the Johns Hopkins Bloomberg School of Public Health ... that triggers an immune response in multiple mosquito species ... -the parasite that causes malaria in humans. By ... block the development of the malaria-causing parasite in ...
Cached Biology News:K-State researchers help Epitopix license the United States' first E. coli O157 vaccine for cattle 2Harmonizing biobank research: An achievable world-wide goal 2Malaria immunity trigger found for multiple mosquito species 2